The neurobiology and treatment of first-episode schizophrenia

被引:164
|
作者
Kahn, R. S. [1 ]
Sommer, I. E. [1 ]
机构
[1] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Dept Psychiat, NL-3584 CX Utrecht, Netherlands
关键词
MAGNETIC-RESONANCE SPECTROSCOPY; ULTRA-HIGH RISK; DRUG-NAIVE PATIENTS; DOPAMINE SYNTHESIS CAPACITY; C-REACTIVE PROTEIN; DORSOLATERAL PREFRONTAL CORTEX; MATERNAL IMMUNE ACTIVATION; NMDA RECEPTOR HYPOFUNCTION; HIGH-AFFINITY STATE; HIGH GENETIC RISK;
D O I
10.1038/mp.2014.66
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It is evident that once psychosis is present in patients with schizophrenia, the underlying biological process of the illness has already been ongoing for many years. At the time of diagnosis, patients with schizophrenia show decreased mean intracranial volume (ICV) as compared with healthy subjects. Since ICV is driven by brain growth, which reaches its maximum size at approximately 13 years of age, this finding suggests that brain development in patients with schizophrenia is stunted before that age. The smaller brain volume is expressed as decrements in both grey and white matter. After diagnosis, it is mainly the grey matter loss that progresses over time whereas white matter deficits are stable or may even improve over the course of the illness. To understand the possible causes of the brain changes in the first phase of schizophrenia, evidence from treatment studies, postmortem and neuroimaging investigations together with animal experiments needs to be incorporated. These data suggest that the pathophysiology of schizophrenia is multifactorial. Increased striatal dopamine synthesis is already evident before the time of diagnosis, starting during the at-risk mental state, and increases during the onset of frank psychosis. Cognitive impairment and negative symptoms may, in turn, result from other abnormalities, such as NMDA receptor hypofunction and low-grade inflammation of the brain. The latter two dysfunctions probably antedate increased dopamine synthesis by many years, reflecting the much earlier presence of cognitive and social dysfunction. Although correction of the hyperdopaminergic state with antipsychotic agents is generally effective in patients with a first-episode psychosis, the effects of treatments to correct NMDA receptor hypofunction or low-grade inflammation are (so far) rather modest at best. Improved efficacy of these interventions can be expected when they are applied at the onset of cognitive and social dysfunction, rather than at the onset of psychosis.
引用
收藏
页码:84 / 97
页数:14
相关论文
共 50 条
  • [31] Course of treatment response in first-episode and chronic schizophrenia
    Szymanski, SR
    Cannon, TD
    Gallacher, F
    Erwin, RJ
    Gur, RE
    AMERICAN JOURNAL OF PSYCHIATRY, 1996, 153 (04): : 519 - 525
  • [32] Insight in first-episode schizophrenia
    Ceskova, Eva
    Prikryl, Radovan
    Kasparek, Tomas
    Kucerova, Hana
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (01) : 36 - 40
  • [33] Evidence-based treatment for first-episode schizophrenia?
    Carpenter, WT
    AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (11): : 1771 - 1773
  • [34] Prolactin levels in risperidone treatment of first-episode schizophrenia
    Cesková, E
    Pkikryl, R
    Kaspárek, T
    Ondrusová, M
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2004, 8 (01) : 31 - 36
  • [35] Comparison of Treatment Response in Second-Episode Versus First-Episode Schizophrenia
    Emsley, Robin
    Oosthuizen, Petrus
    Koen, Liezl
    Niehaus, Dana
    Martinez, Lupe
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2013, 33 (01) : 80 - 83
  • [36] Antipsychotic Treatment of First-Episode or Early-Onset Schizophrenia
    Webb, Trina
    Tandon, Rajiv
    CURRENT PSYCHIATRY REPORTS, 2009, 11 (04) : 261 - 263
  • [37] Antipsychotic treatment of first-episode or early-onset schizophrenia
    Trina Webb
    Rajiv Tandon
    Current Psychiatry Reports, 2009, 11 : 261 - 263
  • [38] Clinical and functional outcome of treatment refractory first-episode schizophrenia
    Phahladira, L.
    Emsley, R.
    Asmal, L.
    Chiliza, B.
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2013, 19 (03) : 104 - 105
  • [39] Time course for antipsychotic treatment response in first-episode schizophrenia
    Emsley, R
    Rabinowitz, J
    Medori, R
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (04): : 743 - 745
  • [40] Effectiveness of genetically-guided treatment in first-episode schizophrenia
    Luck, Marissa
    Turner, Michael
    Shad, Mujeeb U.
    SCHIZOPHRENIA RESEARCH, 2018, 193 : 441 - 442